Stada-Mabxience Bevacizumab Is Latest To Receive EU Nod
As Riemser’s Thiotepa And Teva Inhalers Also Endorsed By CHMP
Stada and Mabxience have received an endorsement from the EMA for their partnered bevacizumab biosimilar rival to Avastin. Meanwhile, Riemser’s thiotepa generic and two Teva inhalers have also received positive opinions from the CHMP.
You may also be interested in...
Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.
Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.
Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.